|
1
|
Howlader N, Cronin KA, Kurian AW and
Andridge R: Differences in breast cancer survival by molecular
subtypes in the United States. Cancer Epidemiol Biomarkers Prev.
27:619–626. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomized multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wildiers H, Forceville K, Paridaens R and
Joensuu H: Taxanes and anthracyclines in early breast cancer: Which
first? Lancet Oncol. 11:219–220. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Earl HM, Vallier AL, Hiller L, Fenwick N,
Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam
K, et al: Effects of the addition of gemcitabine, and
paclitaxel-first sequencing, in neoadjuvant sequential epirubicin,
cyclophosphamide, and paclitaxel for women with high-risk early
breast cancer (Neo-tAnGo): An open-label, 2x2 factorial randomised
phase 3 trial. Lancet Oncol. 15:201–212. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Iwata H, Sato N, Masuda N, Nakamura S,
Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y and
Toi M: Docetaxel followed by
fluorouracil/epirubicin/cyclophosphamide as neoadjuvant
chemotherapy for patients with primary breast cancer. Jpn J Clin
Oncol. 41:867–875. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Joensuu H, Bono P, Kataja V, Alanko T,
Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S,
Möykkynen K, et al: Fluorouracil, epirubicin, and cyclophosphamide
with either docetaxel or vinorelbine, with or without trastuzumab,
as adjuvant treatments of breast cancer: Final results of the
FinHer trial. J Clin Oncol. 27:5685–5692. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schneeweiss A, Chia S, Hickish T, Harvey
V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, et al:
Pertuzumab plus trastuzumab in combination with standard
neoadjuvant anthracycline-containing and anthracycline-free
chemotherapy regimens in patients with HER2-positive early breast
cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann
Oncol. 24:2278–2284. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van Ramshorst MS, van der Voort A, van
Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop
AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with
or without anthracyclines in the presence of dual HER2 blockade for
HER2-positive breast cancer (TRAIN-2): A multicentre, open-label,
randomized, phase 3 trial. Lancet Oncol. 19:1630–1640.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
van der Voort A, van Ramshorst MS, van
Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop
AH, Tick LW, van de Wouw AJ, et al: Three-year follow-up of
neoadjuvant chemotherapy with or without anthracyclines in the
presence of dual ERBB2 blockade in patients with ERBB2-positive
breast cancer: A secondary analysis of the TRAIN-2 randomized,
phase 3 trial. JAMA Oncol. 7:978–984. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gianni L, Pienkowski T, Im YH, Tseng LM,
Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA,
Pedrini JL, et al: 5-Year analysis of neoadjuvant pertuzumab and
trastuzumab in patients with locally advanced, inflammatory, or
early-stage HER2-positive breast cancer (NeoSphere): A multicentre,
open-label, phase 2 randomised trial. Lancet Oncol. 17:791–800.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mamounas EP, Untch M, Mano MS, Huang CS,
Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S,
DiGiovanna MP, et al: Adjuvant T-DM1 versus trastuzumab in patients
with residual invasive disease after neoadjuvant therapy for
HER2-positive breast cancer: Subgroup analyses from KATHERINE. Ann
Oncol. 32:1005–1014. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Broglio KR, Quintana M, Foster M, Olinger
M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S,
Dent S, et al: Association of pathologic complete response to
neoadjuvant therapy in HER2-positive breast cancer with long-term
outcomes: A meta-analysis. JAMA Oncol. 2:751–760. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Untch M, Rezai M, Loibl S, Fasching PA,
Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B,
et al: Neoadjuvant treatment with trastuzumab in HER2-positive
breast cancer: Results from the GeparQuattro study. J Clin Oncol.
28:2024–2031. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Modi S, Saura C, Yamashita T, Park YH, Kim
SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive breast
cancer. N Engl J Med. 382:610–621. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
File D, Curigliano G and Carey LA:
Escalating and de-escalating therapy for early-stage HER2-positive
breast cancer. Am Soc Clin Oncol Educ Book. 40:1–11.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tolaney SM, Guo H, Pernas S, Barry WT,
Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay
M, et al: Seven-year follow-up analysis of adjuvant paclitaxel and
trastuzumab trial for node-negative, human epidermal growth factor
receptor 2-positive breast cancer. J Clin Oncol. 37:1868–1875.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pernas S and Tolaney SM: Management of
early-stage human epidermal growth factor receptor 2-positive
breast cancer. JCO Oncol Pract. 17:320–330. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fujita N, Fujita K, Kim SJ, Iguchi C,
Nomura T, Aono T, Yanagisawa T, Enomoto Y, Inakami K, Miyagawa Y,
et al: Response-guided omission of anthracycline in patients with
HER2-positive early breast cancer treated with neoadjuvant taxane
and trastuzumab: 5-Year follow-up of prognostic study using
propensity score matching. Oncology. 100:257–266. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
von Minckwitz G, Procter M, de Azambuja E,
Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N,
Clark E, et al: Adjuvant pertuzumab and trastuzumab in early
HER2-positive breast cancer. N Engl J Med. 377:122–131.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yu N, Leung VWY and Meterissian S: MRI
performance in detecting pCR after neoadjuvant chemotherapy by
molecular subtype of breast cancer. World J Surg. 43:2254–2261.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Marinovich ML, Houssami N, Macaskill P,
Sardanelli F, Irwig L, Mamounas EP, von Minckwitz G, Brennan ME and
Ciatto S: Meta-analysis of magnetic resonance imaging in detecting
residual breast cancer after neoadjuvant therapy. J Natl Cancer
Inst. 105:321–333. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Iwase M, Sawaki M, Hattori M, Yoshimura A,
Ishiguro J, Kotani H, Gondo N, Adachi Y, Kataoka A, Onishi S, et
al: Assessing residual cancer cells using MRI and US after
preoperative chemotherapy in primary breast cancer to omit surgery.
Breast Cancer. 25:583–589. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yuan Y, Chen XS, Liu SY and Shen KW:
Accuracy of MRI in prediction of pathologic complete remission in
breast cancer after preoperative therapy: A meta-analysis. AJR Am J
Roentgenol. 195:260–268. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Heil J, Schaefgen B, Sinn P, Richter H,
Harcos A, Gomez C, Stieber A, Hennigs A, Rauch G, Schuetz F, et al:
Can a pathological complete response of breast cancer after
neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Eur J Cancer. 69:142–150. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Heil J, Kümmel S, Schaefgen B, Paepke S,
Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, et
al: Diagnosis of pathological complete response to neoadjuvant
chemotherapy in breast cancer by minimal invasive biopsy
techniques. Br J Cancer. 113:1565–1570. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hayashi N, Kumamaru H, Isozumi U, Aogi K,
Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, et al:
Annual report of the Japanese breast cancer registry for 2017.
Breast Cancer. 27:803–809. 2020.PubMed/NCBI View Article : Google Scholar
|
